Tammy Harvey, DO
Allergy & Immunology · Metairie, LANPI 1013108463
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 371 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 16.8% — the pattern of someone who eats at a lot of different presentations.
Across 371 payments — averaging $17.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$862
- Genentech USA, Inc.$674
- Takeda Pharmaceuticals U.S.A., Inc.$620
- Regeneron Healthcare Solutions, Inc.$502
- Pfizer$455
- plus $2K from 30 others
What the payments were for
- Consulting fees$240%
- Food & beverage$6,51998%
- Education$971%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 46 | $1,115 |
| GSK | 60 | $862 |
| Genentech USA, Inc. | 26 | $674 |
| Takeda Pharmaceuticals U.S.A., Inc. | 35 | $620 |
| Regeneron Healthcare Solutions, Inc. | 23 | $502 |
| Pfizer | 27 | $455 |
| Sanofi | 18 | $321 |
| AbbVie | 9 | $234 |
| CSL Behring | 13 | $231 |
| Teva Pharmaceuticals USA, Inc. | 33 | $198 |
| Grifols USA, LLC | 10 | $189 |
| Amgen | 6 | $122 |
| Optinose US, Inc. | 7 | $114 |
| Boehringer Ingelheim | 7 | $101 |
| Greer Laboratories, Inc. | 7 | $96 |
| Shire North American Group Inc | 6 | $85 |
| Aimmune Therapeutics, Inc. | 4 | $83 |
| Johnson & Johnson | 1 | $66 |
| Novartis | 3 | $66 |
| ADMA Biomanufacturing LLC | 5 | $65 |
| Kaleo, Inc. | 4 | $60 |
| Alk-abello, Inc | 3 | $47 |
| Incyte Corporation | 2 | $42 |
| Eyevance Pharmaceuticals LLC | 2 | $34 |
| Biocryst US Sales Co., LLC | 2 | $33 |
| Bio Products Laboratory USA, Inc. | 2 | $28 |
| Smith+Nephew | 1 | $27 |
| Kedrion Biopharma, Inc. | 1 | $25 |
| LEO Pharma Inc. | 1 | $23 |
| Pharming Healthcare, Inc. | 1 | $21 |
| Hikma Pharmaceuticals USA | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| USWM, LLC | 1 | $18 |
| Phadia US Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $16 |
| Boston Scientific | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$253
- TEZSPIRE$253
- FASENRA$253
- FLUMIST QUADRIVALENT$149
- DUPIXENT$122
How this compares
$6,640 in reported general payments places this provider in the 65th percentile of 62 allergy & immunology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 50 | $217,270 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 30 | $181,757 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 36 | $170,872 |
| XolairOmalizumab | 35 | $129,458 |
| XembifyImmune Globulin,gamma(Igg)klhw | 13 | $77,043 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 60 | $37,626 |
| Epinephrine | 52 | $9,365 |
| Ipratropium Bromide | 161 | $5,137 |
| Azelastine Hcl | 89 | $2,403 |
| Cefdinir | 53 | $944 |
| Doxycycline Hyclate | 87 | $899 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 40 | $899 |
| Triamcinolone Acetonide | 48 | $677 |
| Fluconazole | 14 | $411 |
| Esomeprazole Magnesium | 15 | $407 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Grifols USA, LLCGamunex-C, Xembify | $189 | $294,31263 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $620 | $181,75730 claims |
| CSL BehringHizentra | $231 | $170,87236 claims |
| GSKTrelegy Ellipta | $862 | $37,62660 claims |
| Hikma Pharmaceuticals USAEpinephrine | $19 | $9,36552 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 62 allergy & immunology providers in Louisiana.
Other allergy & immunology in Metairie
- Sarah QayumMetairie$11K
- David SchneiderMetairie$10K
- Jeffery FranklinMetairie$9K
- Sweta ShahMetairie$7K
- Alice HoytMetairie$7K
- Alan SheenMetairie$4K
- David KaufmanShreveport$678K
- Reena MehtaNew Orleans$159K
- Kenneth ParisNew Orleans$150K
- Brice RolstonCovington$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.